Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 October 2020Website:
http://immunome.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
IMNM Latest News
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations.
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago.
Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company specializing in innovative targeted cancer treatments, has promoted Max Rosett to Chief Financial Officer, starting May 9. Mr. Rosett, who previously served as Executive Vice President of Operations and Interim CFO since January 2024, played a key role in Immunome's swift evolution.
Immunome, Inc. (IMNM) reported a quarterly loss of $0.34 per share, which beat the Zacks Consensus Estimate of a loss of $0.80. This is an improvement from the loss of $0.35 per share reported a year ago.
Immunome (IMNM) lacks the necessary combination of key elements for a potential earnings surprise in its upcoming report. Be ready for the important projections.
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25. IMNM is also looking to acquire some antibody-related assets and materials from Atreca, subject to a stockholder vote.
What type of business is Immunome?
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
What sector is Immunome in?
Immunome is in the Healthcare sector
What industry is Immunome in?
Immunome is in the Biotechnology industry
What country is Immunome from?
Immunome is headquartered in United States
When did Immunome go public?
Immunome initial public offering (IPO) was on 02 October 2020
What is Immunome website?
https://immunome.com
Is Immunome in the S&P 500?
No, Immunome is not included in the S&P 500 index
Is Immunome in the NASDAQ 100?
No, Immunome is not included in the NASDAQ 100 index
Is Immunome in the Dow Jones?
No, Immunome is not included in the Dow Jones index
When was Immunome the previous earnings report?
No data
When does Immunome earnings report?
The next expected earnings date for Immunome is 08 November 2024